Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.
Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings
In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper versions known as compounded drugs.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The announcement is a blow to the compounding pharmacies that have made cheaper, off-brand versions of the medication The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over,
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
Lilly's weight-loss, diabetes drugs no longer in shortage, pressuring Hims and Hers' stock
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding manufacturing.
England's NHS to offer Lilly's weight-loss drug to some patients
England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a three-year plan, the country's drugs cost regulator said on Thursday. The drug,
GLP-1 medications, their effect on bariatrics and cautions for people seeking weight loss without surgery
Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...
Glamour on MSN3h
Do GLP-1 Supplements Work? Doctors Set the Record Straight on 'Nature's Ozempic'
Brands like Kourtney Kardashian's Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
GlobalData on MSN1d
Social media algorithms are driving the the GLP-1 drugs boom
GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might ...
Benefits Pro24d
The gut health crisis: Impact of GLP-1 medications on digestive wellness
Now, providers and employers are also dealing with GI side effects from popular GLP-1 medications, which are used to treat type 2 diabetes and weight loss. While these drugs have helped ...
Becker's Hospital Review11d
Inside the GLP-1 'price war'
According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...
The Business Journals22d
Insurance execs share what employers need to know about the craze for GLP-1 weight loss medications
According to a recent article in the American Journal of Managed Care, the list price for GLP-1 drugs can range from $936 to $1,349 before insurance and other discounts. Costs are rising so ...
FiercePharma1d
Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
News Medical14d
Bariatric surgery outperforms GLP-1 medications in protecting kidney function
Among the study participants, 183 patients underwent bariatric surgery while 242 patients were treated with GLP-1 receptor agonist medications. Patients involved in the study underwent bariatric ...
Science Daily21d
Key factors that impact long-term weight loss in patients prescribed GLP-1 RA medications
or GLP-1 RA medications. Those FDA-approved medications help lower blood sugar levels and promote weight loss. Obesity is a complex chronic disease that affects more than 41% of the U.S. adult ...